Company news

Collplant Biotechnologies Ltd. (NASDAQ:CLGN) news

Every Collplant Biotechnologies Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Collplant Biotechnologies Ltd. →

Press releases — page 2

CollPlant Issues Letter to Shareholders

February 14, 2024

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California

January 7, 2024

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

January 1, 2024

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

November 28, 2023

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

November 8, 2023

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

October 31, 2023

CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative

September 20, 2023

CollPlant to Present at the H.C. Wainwright Annual Growth Conference

September 4, 2023

CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million

August 23, 2023

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

August 8, 2023

CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement

June 25, 2023

CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update

May 23, 2023

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

May 1, 2023

BioHarvest Sciences Hires Dr. Ilana Belzer as Chief Operating Officer

April 18, 2023

Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs

April 3, 2023

Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update

March 28, 2023

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

March 13, 2023

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

January 3, 2023

CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

January 2, 2023

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results

November 30, 2022

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

November 14, 2022

CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90

November 6, 2022

CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

November 2, 2022

CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

October 2, 2022

CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

September 18, 2022

CollPlant Biotechnologies to Participate in September Investor Conferences

September 5, 2022

CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results

August 24, 2022

CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada

July 4, 2022

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

June 27, 2022

CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results

May 25, 2022

CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening

April 24, 2022

CollPlant To Present at the Aesthetics Innovation Summit 2022

April 12, 2022

CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results

March 23, 2022

CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies

February 15, 2022

CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal

December 1, 2021

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results

November 17, 2021

CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs

November 14, 2021

CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st

October 13, 2021

CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs

October 10, 2021

CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021

September 29, 2021

CollPlant CEO Yehiel Tal to Discuss Emerging Uses of rhCollagen in Aesthetic and Regenerative Medicine at NANO.IL.2021 Conference

September 26, 2021

CollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF)

September 8, 2021

CollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September

September 6, 2021

CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results

August 18, 2021

CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

August 18, 2021

CollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Organs at the Biomaterials For 3D Printing Webinar

August 15, 2021

3D Systems and CollPlant Enter Co-development Agreement to Deliver Bioprinted Solutions for Improved Breast Reconstruction Treatments

June 21, 2021

CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs

June 3, 2021

CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million

May 26, 2021

CollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs

May 24, 2021

← Newer · Older →